echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The second phase of the new crown vaccine data of the high-end vaccine is reviewed and published in The Lancet-Respiratory Diseases

    The second phase of the new crown vaccine data of the high-end vaccine is reviewed and published in The Lancet-Respiratory Diseases

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Taipei, October 18, 2021 /PRNewswire The data from the Phase II clinical trial of MVC-COV1901 vaccine (referred to as "high-end vaccine") showed good immunogenicity and safety


    The study was conducted from December 30, 2020 to April 2, 2021.


    The test results showed that based on wild-type SARS-CoV-2 GMT, the seroconversion rate of the MVC-COV1901 group on day 57 was 99.


    The SARS-CoV-2 antigen design used in the MVC-COV1901 vaccine was approved by the National Institutes of Health (NIH), in which a series of genetic modifications were made to the S-2P fusion prospine protein


    In summary, the interim analysis shows that the MVC-COV1901 vaccine has good safety and a good neutralizing antibody titer


    The results of this research have become the basis for immune bridging, enabling the MVC-COV1901 vaccine to obtain an "emergency use authorization" in Taiwan and help support subsequent development progress


    Introduction to High-end Vaccine Biologics Co.


    High-end Vaccine Biologics Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.